142.49
+0.15(+0.11%)
Currency In USD
| Previous Close | 142.34 |
| Open | 141.08 |
| Day High | 143.98 |
| Day Low | 141.07 |
| 52-Week High | 246.44 |
| 52-Week Low | 139.71 |
| Volume | 1.04M |
| Average Volume | 1.49M |
| Market Cap | 20.76B |
| PE | 12.9 |
| EPS | 11.05 |
| Moving Average 50 Days | 151.13 |
| Moving Average 200 Days | 192.5 |
| Change | 0.15 |
If you invested $1000 in Biogen Inc. (BIIB) 10 years ago, it would be worth $354.64 as of February 05, 2025 at a share price of $142.49. Whereas If you bought $1000 worth of Biogen Inc. (BIIB) shares 5 years ago, it would be worth $428.07 as of February 05, 2025 at a share price of $142.49.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
GlobeNewswire Inc.
Jan 31, 2025 11:30 AM GMT
TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
GlobeNewswire Inc.
Jan 23, 2025 12:30 PM GMT
Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMACAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq:
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
GlobeNewswire Inc.
Jan 14, 2025 12:05 AM GMT
LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration optionTOKYO and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquar